These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
57 related articles for article (PubMed ID: 6390848)
1. Ineffective cellular interaction and interleukin 2 deficiency causing T cell defects in human allogeneic marrow recipients early after grafting and in those with chronic graft-versus-host disease. Tsoi MS; Mori T; Brkic S; Dobbs S; Gillis S; Santos E; Thomas ED; Storb R Transplant Proc; 1984 Dec; 16(6):1470-2. PubMed ID: 6390848 [TBL] [Abstract][Full Text] [Related]
2. Cellular interactions in marrow-grafted patients. II. Normal monocyte antigen-presenting and defective T-cell-proliferative functions early after grafting and during chronic graft-versus-host disease. Tsoi MS; Dobbs S; Brkic S; Ramberg R; Thomas ED; Storb R Transplantation; 1984 Jun; 37(6):556-61. PubMed ID: 6233768 [TBL] [Abstract][Full Text] [Related]
3. Cellular interactions in marrow-grafted patients. III. Normal interleukin 1 and defective interleukin 2 production in short-term patients and in those with chronic graft-versus-host disease. Brkic S; Tsoi MS; Mori T; Lachman L; Gillis S; Thomas ED; Storb R Transplantation; 1985 Jan; 39(1):30-5. PubMed ID: 3880962 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of prostaglandin E2 restores defective lymphocyte proliferation and cell-mediated lympholysis in recipients after allogeneic marrow grafting. Klingemann HG; Tsoi MS; Storb R Blood; 1986 Jul; 68(1):102-7. PubMed ID: 2941083 [TBL] [Abstract][Full Text] [Related]
5. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2. Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666 [TBL] [Abstract][Full Text] [Related]
6. IL-7 drives donor T cell proliferation and can costimulate cytokine secretion after MHC-matched allogeneic bone marrow transplantation. Levy RB; Jones M; Hamilton BL; Paupe J; Horowitz T; Riley R J Immunol; 1995 Jan; 154(1):106-15. PubMed ID: 7995931 [TBL] [Abstract][Full Text] [Related]
7. Proliferation of peripheral lymphocytes to interleukin-2 and interleukin-4 after marrow transplantation. Klingemann HG; Kohn FR; Phillips GL Eur Cytokine Netw; 1991; 2(2):131-6. PubMed ID: 1813016 [TBL] [Abstract][Full Text] [Related]
8. The identification and characteristics of IL-22-producing T cells in acute graft-versus-host disease following allogeneic bone marrow transplantation. Zhao K; Zhao D; Huang D; Song X; Chen C; Pan B; Wu Q; Cao J; Yao Y; Zeng L; Xu K Immunobiology; 2013 Dec; 218(12):1505-13. PubMed ID: 23816304 [TBL] [Abstract][Full Text] [Related]
9. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation. Russell CA Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093 [TBL] [Abstract][Full Text] [Related]
10. Cellular interactions in marrow-grafted patients. I. Impairment of cell-mediated lympholysis associated with graft-vs-host disease and the effect of interleukin 2. Mori T; Tsoi MS; Gillis S; Santos E; Thomas ED; Storb R J Immunol; 1983 Feb; 130(2):712-6. PubMed ID: 6217250 [TBL] [Abstract][Full Text] [Related]
11. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution. Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113 [TBL] [Abstract][Full Text] [Related]
12. Lethal graft-vs-host disease across major histocompatibility barriers: requirement for leucyl-leucine methyl ester sensitive cytotoxic T cells. Thiele DL; Charley MR; Calomeni JA; Lipsky PE J Immunol; 1987 Jan; 138(1):51-7. PubMed ID: 2946780 [TBL] [Abstract][Full Text] [Related]
13. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736 [TBL] [Abstract][Full Text] [Related]
14. Generation of CD8 cytolytic T cells early after autologous or allogeneic bone marrow transplantation. Charmot D; Ragueneau M; Olive D; Maraninchi D; Mawas C Bone Marrow Transplant; 1987 Aug; 2(2):183-94. PubMed ID: 2901879 [TBL] [Abstract][Full Text] [Related]
15. Measurement of recipient-specific alloreactivity: is GVHD predictable? Theobald M; Bunjes D; Nierle T; Arnold R; Heimpel H Bone Marrow Transplant; 1993; 12 Suppl 3():S18-23. PubMed ID: 8124251 [TBL] [Abstract][Full Text] [Related]
16. Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice. Perreault C; Allard A; Brochu S; Poupart C; Fontaine P; Bélanger R; Gyger M Bone Marrow Transplant; 1990 Aug; 6(2):127-35. PubMed ID: 2145050 [TBL] [Abstract][Full Text] [Related]
17. Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation. Buckley RH; Schiff SE; Sampson HA; Schiff RI; Markert ML; Knutsen AP; Hershfield MS; Huang AT; Mickey GH; Ward FE J Immunol; 1986 Apr; 136(7):2398-407. PubMed ID: 2869085 [TBL] [Abstract][Full Text] [Related]
18. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Jun HX; Jun CY; Yu ZX Haematologica; 2004 Dec; 89(12):1517-24. PubMed ID: 15590404 [TBL] [Abstract][Full Text] [Related]